Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial-Reference-Cited by-同舟云学术

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

Published:2024-03 Issue:3 Volume:25 Page:317-325
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Palmieri Carlo,Linden Hannah,Birrell Stephen N,Wheelwright Sally,Lim Elgene,Schwartzberg Lee S,Dwyer Amy R,Hickey Theresa E,Rugo Hope S,Cobb Patrick,O'Shaughnessy Joyce A,Johnston Stephen,Brufsky Adam,Tilley Wayne D,Overmoyer Beth

Publisher

Elsevier BV

Reference32 articles.

1. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer;Hickey;Nat Med,2021

2. Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers;Freelander;Cancer Res,2022

3. The use of testosterone propionate in the treatment of advanced carcinoma of the breast;Adair;Ann Surg,1946

4. Fluoxymesterone therapy in advanced breast cancer;Kennedy;N Engl J Med,1958

5. Testosterone propionate therapy in breast cancer;Goldenberg;JAMA,1964

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics;Steroids;2024-10

2. Ernährungsmedizin in der Onkologie - ein Update;Im Fokus Onkologie;2024-09

3. The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals;Best Practice & Research Clinical Endocrinology & Metabolism;2024-09

4. Evidence of ostarine excretion in oral fluid after a single controlled oral administration;Clinica Chimica Acta;2024-04

5. Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer;The Lancet Oncology;2024-03